1. Search Result
Search Result
Results for "

A new oral cox 2 specitic Inhibitors

" in MedChemExpress (MCE) Product Catalog:

9978

Inhibitors & Agonists

102

Screening Libraries

88

Fluorescent Dye

88

Biochemical Assay Reagents

123

Peptides

2

MCE Kits

16

Inhibitory Antibodies

1111

Natural
Products

2920

Recombinant Proteins

683

Isotope-Labeled Compounds

830

Antibodies

51

Click Chemistry

209

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14445

    cox-2 Inhibitor V

    COX Inflammation/Immunology
    FK 3311 (COX-2 Inhibitor V) is a selective inhibitor of COX-2 with antiinflammatory agent.
    FK 3311
  • HY-147794

    COX Cancer
    COX-2-IN-18 (Compound 3) is a potent inhibitor of COX-2. COX-2-IN-18 possesses good COX-2 inhibitory activity (IC50 = 0.775 μM) compared to the reference agent, Celecoxib (IC50 = 0.153 μM). COX-2-IN-18 has the potential for the research of cancer diseases .
    COX-2-IN-18
  • HY-115936

    COX Inflammation/Immunology
    COX-2-IN-9 (compound 7a) is a potent, selective, and orally active inhibitor of COX-2 with an IC50 of 10.17 uM. COX-2-IN-9 has higher COX-2 selectivity than Celecoxib. COX-2-IN-9 shows good in vivo anti-inflammatory and low ulcerogenic activity .
    COX-2-IN-9
  • HY-115934

    COX Inflammation/Immunology
    COX-2-IN-7 (compound 4a) is a potent, selective, and orally active inhibitor of COX-2 with an IC50 of 6.585 uM. COX-2-IN-7 has higher COX-2 selectivity than Celecoxib. COX-2-IN-7 shows good in vivo anti-inflammatory and low ulcerogenic activity .
    COX-2-IN-7
  • HY-115935

    COX Inflammation/Immunology
    COX-2-IN-8 (compound 6a) is a potent, selective, and orally active inhibitor of COX-2 with an IC50 of 6.585 uM. COX-2-IN-8 has higher COX-2 selectivity than Celecoxib. COX-2-IN-8 shows good in vivo anti-inflammatory and low ulcerogenic activity .
    COX-2-IN-8
  • HY-147961

    COX Inflammation/Immunology
    COX-2-IN-23 (compound 9a) is a selective COX-2 inhibitor with IC50 values of 0.28 and 20.14 μM for COX-2 and COX-1. COX-2-IN-23 has anti-inflammatory activity and low ulcerogenic activity.
    COX-2-IN-23
  • HY-168070

    COX NF-κB NO Synthase Inflammation/Immunology
    COX-2-IN-48 (5-25), a COX-2 inhibitor with an IC50 of 51.7 nM for human COX-2, exerts anti-inflammatory and analgesic effects in various rodent models by inhibiting NF-κB pathway. COX-2-IN-48 (5-25) inhibits the degradation of IκB, the phosphorylation and nuclear translocation of NF-κB p65, and the expression of COX-2 and iNOS .
    COX-2-IN-48
  • HY-161862

    COX Inflammation/Immunology
    COX-2-IN-44 is a potent and orally active COX-2 inhibitor with IC50 values of 0.18,1.14 µM for COX-2, COX-1, respectively. COX-2-IN-44 shows anti-inflammatory activity .
    COX-2-IN-44
  • HY-162244

    COX Inflammation/Immunology
    COX-2-IN-40 (compound 17) is a COX-2 inhibitor with the IC50 of 14.86 μM. COX-2-IN-40 can be used for study of chronic pain .
    COX-2-IN-40
  • HY-161147

    COX Inflammation/Immunology
    COX-2-IN-37 (compound 11) is a potent and selective COX-2 inhibitor. COX-2-IN-37 has strong antioxidant activity with an IC50 of 33.0 μg/mL .
    COX-2-IN-37
  • HY-157578

    COX Inflammation/Immunology
    COX-2-IN-38 (compound 52*) is a potent inhibitor of COX-2, with the IC50 value of 79.4 nM .
    COX-2-IN-38
  • HY-157583

    COX Others
    COX-2-IN-39 (compound 44) is a potent inhibitor of COX-2, with the IC50 value of 0.4 nM .
    COX-2-IN-39
  • HY-156254

    COX Inflammation/Immunology
    COX-2-IN-35 (compound 7) is a selective COX-2 inhibitor with an IC50 of 4.37 nM. COX-2-IN-35 has anti-inflammatory activity .
    COX-2-IN-35
  • HY-145988

    COX Inflammation/Immunology
    COX-2-IN-11 (compound 7b2) is a potent and selective inhibitor of COX-2. COX-2-IN-11 has the potential for the research of inflammation diseases .
    COX-2-IN-11
  • HY-161994

    COX Inflammation/Immunology
    COX-2-IN-47 (compound 6c ) is a selective COX-2 inhibitor with IC50 value of 0.03 μM. COX-2-IN-47 has antiedema activity .
    COX-2-IN-47
  • HY-146161

    COX NO Synthase Inflammation/Immunology
    COX-2/NO-IN-1 is an orally active nitric oxide synthase (iNOS), COX-2 expression and NO (IC50 of 3.52 μM) inhibitor. COX-2/NO-IN-1 has anti-inflammatory effects .
    COX-2/NO-IN-1
  • HY-147692

    COX Inflammation/Immunology
    COX-2-IN-14 (compound 2a) is a potent and selective COX-2 (cyclooxygenase-2) inhibitor. COX-2-IN-14 shows effective binding at the active site of COX-2 co-crystal. COX-2-IN-14 exhibits a high level of in vivo anti-inflammatory activity, reducing ear edema and myeloperoxidase (MPO) activity in mice .
    COX-2-IN-14
  • HY-159562

    COX Inflammation/Immunology
    COX-2-IN-46 (compound 5m) is an anti-inflammatory agent with potent analgesic activity. COX-2-IN-46 exhibits a significant inhibitory effect on COX-2 (IC50=87.74 nM) .
    COX-2-IN-46
  • HY-150721

    COX Neurological Disease Inflammation/Immunology
    COX-2-IN-29 (Compound 15b) is a selective and orally active COX-2 inhibitor with an IC50 of 0.005 μM .
    COX-2-IN-29
  • HY-146371

    COX Inflammation/Immunology
    COX-2-IN-13 (compound 13e) is a potent and selective inhibitor of COX-2 with an IC50 of 0.98 μM. COX-2-IN-13 is an anti-inflammatory agent. COX-2-IN-13 shows safety in-vivo acute toxicity study .
    COX-2-IN-13
  • HY-146370

    COX Inflammation/Immunology
    COX-2-IN-12 (compound 3b) is a potent and selective inhibitor of COX-2 with an IC50 of 19.98 μM. COX-2-IN-12 is an anti-inflammatory agent. COX-2-IN-12 shows safety in-vivo acute toxicity study .
    COX-2-IN-12
  • HY-147719

    COX Inflammation/Immunology
    COX-2-IN-16 (compound 2b) is a potent, selective and orally active COX-2 inhibitor with an IC50 of 102 µM. COX-2-IN-16 inhibits the NO production. COX-2-IN-16 shows anti-inflammatory activity .
    COX-2-IN-16
  • HY-149270

    COX Inflammation/Immunology
    COX-2-IN-31 (compound 7b) is an orally active and dual inhibitor of COX-2 (IC50=60 nM) and 5-LOX (IC50=1.9 μM). COX-2-IN-31 also inhibits transmembrane hCA IX(Ki=48.9 nM) and hCA XII(Ki=5.8 nM) activity. COX-2-IN-31 exhibits anti-inflammatory and analgesic activity .
    COX-2-IN-31
  • HY-150550

    COX Inflammation/Immunology
    COX-2-IN-26 is a potent, selective and orally active COX-2 inhibitor with IC50 values of 10.61, 0.067, 1.96 µM for COX-1, COX-2, 15-LOX, respectively. COX-2-IN-26 shows anti-inflammatory activity. COX-2-IN-26 shows gastrointestinal safety profile .
    COX-2-IN-26
  • HY-115866

    COX Cancer
    COX-2-IN-6 (compound 10) is an orally active, gut-restricted and selective cyclooxygenase-2 (COX-2) inhibitor for colorectal Chemoprevention of cancer. COX-2-IN-6 selectively targets COX-2 with an IC50 of 0.84 μM and a Ki of 69 nM. COX-2-IN-6 also inhibits COX-2-driven PGE2 synthesis with an IC50 of 0.60 μM .
    COX-2-IN-6
  • HY-147809

    COX Inflammation/Immunology
    COX-2-IN-20 (Compound 5d) is a selective and orally active COX-2 inhibitor with an IC50 of 17.9 nM. COX-2-IN-20 shows anti-inflammatory activity .
    COX-2-IN-20
  • HY-147963

    COX Infection
    COX-2-IN-24 is an orally active inhibitor of COX-2 with IC50 value of 0.17 μM, shows anti-inflammatory and low ulcerogenic activities.
    COX-2-IN-24
  • HY-161266

    COX NOD-like Receptor (NLR) NF-κB Inflammation/Immunology
    COX-2/NLRP3-IN-1 (Compound 6k) is a COX-2/NLRP3 inhibitor with a IC50 of 1.53 μM for COX-2. COX-2/NLRP3-IN-1 exerts anti-inflammatory effects by inhibiting the NF-κB/NLRP3 signaling pathway .
    COX-2/NLRP3-IN-1
  • HY-147815

    COX Inflammation/Immunology
    COX-2-IN-21 (Compound 5c) is a selective and orally active COX-2 inhibitor with an IC50 of 0.039 μM. COX-2-IN-21 shows promising anti-inflammatory potential .
    COX-2-IN-21
  • HY-159564

    COX NO Synthase Inflammation/Immunology
    iNOS/COX-2-IN-3 (compound 7d) is a dual inhibitor of iNOS and COX-2, with potential anti-inflammatory activity against LPS (HY-D1056)-induced RAW 264.7 cells (IC50=3.48 μM). iNOS/COX-2-IN-3 has good plasma stability, oral activity and gastric safety, and its inhibitory activity on iNOS and COX-2 expression is 5.43-fold and 2.37-fold that of Indomethacin (HY-14397), respectively .
    iNOS/COX-2-IN-3
  • HY-155133

    COX Inflammation/Immunology
    COX-2-IN-34 (compound 8a) is a selective and orally active inhibitor of COX-2 , with an IC50 of 0.42 μM. COX-2-IN-34 has no gastric ulcer toxicity but has anti-inflammatory effects .
    COX-2-IN-34
  • HY-168888

    COX Inflammation/Immunology
    COX-2-IN-52 (Compound 5l) is an orally active and selective COX-2 inhibitor with an IC50 of 54 nM. COX-2-IN-52 can inhibit the release of NO in cells and has anti-inflammatory activity. COX-2-IN-52 has high gastrointestinal safety and can be used in the research of oral anti-inflammatory drugs .
    COX-2-IN-52
  • HY-146704

    Epoxide Hydrolase COX Cardiovascular Disease
    COX-2/sEH-IN-1 (Compound 9c) is an orally active, dual COX-2 and sEH (soluble epoxide hydrolase) inhibitor with IC50 values of 1.24 µM and 0.40 nM against COX-2 and sEH, respectively. COX-2/sEH-IN-1 shows improved anti-inflammatory activity and highly reduced cardiovascular risks .
    COX-2/sEH-IN-1
  • HY-163509

    COX Apoptosis Cancer
    COX-2-IN-43 (Compound MYM4) is a COX-2 inhibitor (IC50: 0.983 and 0.247 μM for COX-1 and COX-2 respectively). COX-2-IN-43 inhibits cancer cell proliferation and colonization, induces apoptosis .
    COX-2-IN-43
  • HY-150553

    COX Inflammation/Immunology
    COX-2-IN-28 is a potent and selective COX-2 inhibitor with IC50 values of 0.054, 2.14, 13.21 µM for COX-2, 15-LOX, COX-1,respectively .
    COX-2-IN-28
  • HY-150551

    COX Inflammation/Immunology
    COX-2-IN-27 is a potent and selective COX-2 inhibitor with IC50 values of 13.22, 0.045, 1.67 µM for COX-1, COX-2, 15-LOX, respectively. COX-2-IN-27 shows anti-inflammatory activity .
    COX-2-IN-27
  • HY-U00275

    COX Inflammation/Immunology
    COX-2-IN-1 is potent and slective COX-2 inhibitor with an IC50 of 3.9 μM.
    COX-2-IN-1
  • HY-147911

    PI3K COX Inflammation/Immunology Cancer
    COX-2/PI3K-IN-1 (compound 5d) is a potent PI3K inhibitor with IC50 value of 1.14 nM. COX-2/PI3K-IN-1 is a selective COX-2 inhibitor with Ki value of 3.24 nM. COX-2/PI3K-IN-1 has anti-inflammatory and anti-cancer properties.
    COX-2/PI3K-IN-1
  • HY-115976

    COX Inflammation/Immunology
    COX-2-IN-10 is a potent COX-2 inhibitor. COX-2-IN-10 inhibits the production of PGE2 in concentration dependent manner (IC50=2.54 µM). COX-2-IN-10 inhibits the expression of iNOS and COX-2 on mRNA and protein level . COX-2-IN-10 inhibits the production of IL-6, TNF-α and IL-1β .
    COX-2-IN-10
  • HY-147912

    PI3K COX Inflammation/Immunology Cancer
    COX-2/PI3K-IN-2 (compound 5f) is a potent PI3K inhibitor with IC50 value of 2.78 nM. COX-2/PI3K-IN-2 is a selective COX-2 inhibitor with Ki value of 3.02 nM. COX-2/PI3K-IN-2 shows anti-inflammatory and anti-cancer properties .
    COX-2/PI3K-IN-2
  • HY-146295

    COX Inflammation/Immunology
    COX-2/5-LOX-IN-2 (5b) is a potent and dual inhibitor of COX-2/5-LOX. COX-2/5-LOX-IN-2 is a benzothiophen-2-yl pyrazole carboxylic acid derivative. COX-2/5-LOX-IN-2 shows the most potent analgesic and anti-inflammatory activities surpassing that of Celecoxib and Indomethacin. COX-2/5-LOX-IN-2 shows potent COX-1, COX-2 and 5-LOX inhibitory activity with IC50s of 5.40, 0.01 and 1.78 μM, respectively .
    COX-2/5-LOX-IN-2
  • HY-146294

    COX Inflammation/Immunology
    COX-2/5-LOX-IN-1 (compound 3a) is a potent and dual inhibitor of COX-2/5-LOX. COX-2/5-LOX-IN-1 is a benzothiophen-2-yl pyrazole carboxylic acid derivative. COX-2/5-LOX-IN-1 shows the most potent analgesic and anti-inflammatory activities surpassing that of Celecoxib and Indomethacin. COX-2/5-LOX-IN-1 shows potent COX-1, COX-2 and 5-LOX inhibitory activity with IC50s of 12.13, 0.4 and 4.96 μM, respectively .
    COX-2/5-LOX-IN-1
  • HY-116947

    COX Inflammation/Immunology
    COX-2-IN-5 (compound 11a) is a potent COX-2 inhibitor with an IC50 value of 0.65 µM. COX-2-IN-5 has the potential for the research of inflammation .
    COX-2-IN-5
  • HY-146198

    COX Inflammation/Immunology
    COX-2-IN-19 (Compound 24) is a potent COX-2 inhibitor with an IC50 of 1.76 μM. COX-2-IN-19 shows in vivo anti-inflammatory activity .
    COX-2-IN-19
  • HY-170585

    COX NF-κB Inflammation/Immunology
    COX-2-IN-51 (E25) is a potent COX-2 inhibitor, with an IC50 of 70.7 nM. COX-2-IN-51 significantly inhibits LPS-induced release of NO and PGE2, expression of COX-2 and iNOS, and activation of NF-κB pathway. COX-2-IN-51 exhibits anti-inflammatory and analgesic effects in diverse murine models through inhibiting NF-κB pathway. COX-2-IN-51 has lower gastrointestinal side effects than Indomethacin (HY-14397) .
    COX-2-IN-51
  • HY-105304

    COX Inflammation/Immunology
    COX-2-IN-36 (compound 1) is a very potent and specific COX-2 inhibitor, with an IC50 of 0.4 μM [2].
    COX-2-IN-36
  • HY-162385

    COX Inflammation/Immunology
    COX-2-IN-42 (Compound T1) is a COX-2 inhibitor, and protects zebrafish against PTZ-induced neuronal damage .
    COX-2-IN-42
  • HY-101655

    COX Inflammation/Immunology
    COX-2-IN-2 is a selective and inducible COX2 inhibitor with an IC50 of 0.24 μM. COX-2-IN-1 is an anti-inflammatory compound with anti-inflammatory and analgesic activities.
    COX-2-IN-2
  • HY-150685

    Topoisomerase Prostaglandin Receptor Apoptosis Inflammation/Immunology Cancer
    Topo I/COX-2-IN-1 (1H-30) is a potential Topo I/COX-2 inhibitor. Topo I/COX-2-IN-1 inhibits COX-2 and Topo I with the IC50 value of 0.24 μM and 4.42 μM, respectively. Topo I/COX-2-IN-1 can induce apoptosis and inhibit migration of cancer cells, has anti-cancer activity .
    Topo I/COX-2-IN-1
  • HY-161294

    COX Cancer
    COX-2-IN-41 (compound 5e) is a selective inhibitor of COX-2 (IC50=1.74 μM). Compared with COX-1, the selectivity IC50 (COX-1)/IC50(COX-2) =16.32 .
    COX-2-IN-41